Jha Sumit Kant, Kannan Sridharan
Department of Medicine, Subharti Medical College, Meerut, Uttar Pradesh, India.
Department of Health Sciences, College of Medicine, Nursing and Health Sciences, Fiji National University, Suva, Fiji.
Int J Appl Basic Med Res. 2016 Jan-Mar;6(1):8-10. doi: 10.4103/2229-516X.173984.
Studies from the west have shown raised prolactin levels in patients with liver disease. Considering the lacunae on Indian context, we conducted the present study with an objective to assess the prolactin levels in patients with cirrhosis and viral hepatitis with or without features of encephalopathy. The data presented here are the results of the preliminary analysis.
The present study was a prospective, cohort study among patients diagnosed as either viral hepatitis or cirrhosis liver. A cohort of normal healthy adults was selected based on history and laboratory investigations (complete blood count, liver and renal function tests). Serum prolactin was measured for all the study participants, and Kruskal-Wallis H-test with post-hoc Dunn's test was used to analyze the significance of the differences in the levels between various groups. Tests of diagnostic accuracy were used to assess the prediction capability of serum prolactin with a cut-off level of 50 ng/ml.
A total of 70 patients (10 - normal healthy; 25 - acute viral hepatitis; 35 - cirrhosis liver) were recruited in the present study with the median (range) age in years of 56 (34-68) and male: female ratio of 2:1. A statistically significant (P < 0.05) increase in the serum prolactin was observed in patients with cirrhosis with or without encephalopathy. But, among the patients with viral hepatitis, a significant elevation was observed only in patients with encephalopathy. Additionally, a statistically significant association was observed between serum prolactin levels with serum bilirubin (ρ =0.67, P = 0.04) and aspartate aminotransferase (ρ =0.72, P = 0.05). A cut-off value of 50 ng/ml of serum prolactin was found to predict the mortality. A total of 4/12 (33.3%) with prolactin value of <50 ng/ml died while 11/23 (47.8%) died with values >50 ng/ml (P < 0.05). Similarly, in patients with viral hepatitis with encephalopathy features, 1/4 (25%) with prolactin value of <50 ng/ml died while among those without any such features (n = 21), 9 (42.9%) died (P < 0.05).
Serum prolactin has a significant association with patients with liver disease and predicts mortality.
西方的研究表明,肝病患者的催乳素水平升高。鉴于印度背景下的空白,我们开展了本研究,旨在评估伴有或不伴有肝性脑病特征的肝硬化和病毒性肝炎患者的催乳素水平。此处呈现的数据是初步分析的结果。
本研究是一项针对诊断为病毒性肝炎或肝硬化的患者的前瞻性队列研究。根据病史和实验室检查(全血细胞计数、肝肾功能检查)选择了一组正常健康成年人。对所有研究参与者测量血清催乳素,并使用Kruskal-Wallis H检验及事后Dunn检验分析各组之间水平差异的显著性。使用诊断准确性测试来评估血清催乳素在截断值为50 ng/ml时的预测能力。
本研究共招募了70名患者(10名正常健康者;25名急性病毒性肝炎患者;35名肝硬化患者),年龄中位数(范围)为56岁(34 - 68岁),男女比例为2:1。在伴有或不伴有肝性脑病的肝硬化患者中,观察到血清催乳素水平有统计学意义的升高(P <